Nabriva Therapeutics plc
NBRV
Rankning i aktier
#39902
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Aktiekurs
$0.63
Senast synkroniserad: 2023-08-29
Marknadsvärde
$284.20K
Förändring (1 dag)
-21.25%
Förändring (1 år)
629,900.02%
Land
IE
Handel Nabriva Therapeutics plc (NBRV)
Kategori
Healthcare
P/S-tal för Nabriva Therapeutics plc (NBRV)
P/S-tal per 2026 TTM: 0
Enligt Nabriva Therapeutics plc senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0. I slutet av 2026 hade företaget ett P/S-tal på 0.
Historik för P/S-tal för Nabriva Therapeutics plc från 2026 till 2026
P/S-tal vid årets slut
| År | P/S-tal | Ändra |
|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | ||
P/S-tal för liknande företag eller konkurrenter
| Företag | P/S-tal | Skillnad i P/S-tal | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
